Company intelligence / Profile preview

Inhalon Biopharma

Carrboro, North Carolina, United Statesinhalon.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Inhalon has completed IND-enabling studies and a landmark Phase 1b study showing that inhaled antibodies achieve much higher concentrations throughout the respiratory tract compared to IV delivery, with no drug-related adverse events. The lead program IN‑002 is advancing into a human challenge Phase 2a trial for RSV in partnership with hVIVO. Preclinical data show rapid viral clearance and strong safety profile. Other pipeline candidates are at preclinical or IND-enabling stages.

Therapeutic areas: Infectious Diseases
Modalities: Monoclonal antibodies (mAbs)Inhaled immunotherapies
Industry: Biotech

Drug pipeline

7 assets

IN-007

6 more assets in the full pipeline.

Partnerships

hVIVO (contract research organization conducting the upcoming human challenge trial for RSV candidate)

Beyond the preview

Go deeper on Inhalon Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inhalon Biopharma.